ABBVIE INC. vs. Vanda Pharmaceuticals Inc.
ABBVIE INC. (ABBV) comes out ahead, leading on 7 of 8 compared factors.
Size & Scale
| ABBV | VNDA | |
|---|---|---|
| Market Cap | $434.78 billion | $302.31 million |
| Revenue (TTM) | $64.39 billion | $215.72 million |
| Net Income (TTM) | $6.32 billion | $-274,853,000 |
ABBV leads on 3 of 3 size & scale factors.
Valuation
| ABBV | VNDA | |
|---|---|---|
| P/E Ratio | 69.50 | — |
| Price / Book | -73.84 | 1.37 |
| Price / Sales | 6.75 | 1.40 |
ABBV and VNDA split the valuation factors evenly.
Profitability
| ABBV | VNDA | |
|---|---|---|
| Net Margin | 9.81% | -127.41% |
| Return on Equity | -107.29% | -124.83% |
ABBV leads on 2 of 2 profitability factors.
Dividend
| ABBV | VNDA | |
|---|---|---|
| Dividend Yield | 2.81% | — |
| Payout Ratio | 195.48 | — |
ABBV and VNDA split the dividend factors evenly.
Risk & Sentiment
| ABBV | VNDA | |
|---|---|---|
| Short Interest | 0.85% | 2.58% |
ABBV leads on 1 of 1 risk & sentiment factors.
Dig deeper: ABBV overview, ABBV financials, VNDA overview, VNDA financials.
Comparisons use delayed, cached fundamental data and cover only the factors shown. For informational purposes only — not investment advice.